Outlook Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-62.4M | $-75.4M | $-59.0M | $-66.1M | $-53.2M | $-35.2M | $-34.5M | $-30.1M |
| Depreciation & Amortization | $117.1K | $113.9K | $44.2K | $204.7K | $262.1K | $219.4K | $3.4M | $3.1M |
| Depreciation | — | — | — | $163.6K | $163.6K | $219.4K | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $8.9M | $5.4M | $5.5M | $7.7M | $4.9M | $2.8M | $1.3M | $2.0M |
| Net Cash from Operating Activities | $-51.8M | $-68.8M | $-43.0M | $-56.7M | $-54.3M | $-31.8M | $-32.3M | $-33.0M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | $437.3K | $2.8M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | — | — | — | — | $-900.0K | $-437.3K | $-2.8M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $45.0M | $60.3M | $49.0M | $59.6M | $56.2M | $37.2M | $39.0M | $34.4M |
| Net Change in Cash | $-6.8M | $-8.5M | $6.0M | $2.9M | $1.9M | $4.5M | $6.3M | $-1.5M |
| Free Cash Flow | — | — | — | — | — | — | $-32.7M | $-35.8M |